Journal Scans
Tumour Response and Secondary Resectability of Colorectal Liver Metastases Following Neoadjuvant Chemotherapy With Cetuximab: The CELIM Randomised Phase 2 Trial
Effect of Cetuximab on Resectability of Colorectal Liver Metastases
G Folprecht, T Gruenberger, WO Bechstein, H-R Raab, F Lordick, JT Hartmann, H Lang, A Frilling, J Stoehlmacher, J Weitz, R Konopke, C Stroszczynski, T Liersch, D Ockert, T Herrmann, E Goekkurt, F Parisi, C-H Köhne
20100001
2010 Jan 1
Lancet Oncol
Tumour Response and Secondary Resectability of Colorectal Liver Metastases Following Neoadjuvant Chemotherapy With Cetuximab: The CELIM Randomised Phase 2 Trial
Lancet Oncol. 2010 Jan 1;11(1):38-47, G Folprecht, T Gruenberger, WO Bechstein, H-R Raab, F Lordick, JT Hartmann, H Lang, A Frilling, J Stoehlmacher, J Weitz, R Konopke, C Stroszczynski, T Liersch, D Ockert, T Herrmann, E Goekkurt, F Parisi, C-H Köhne
TAKE-HOME MESSAGE
Abstract
Abstract
Background: Neoadjuvant chemotherapy for unresectable colorectal liver metastases can downsize tumours for curative resection. We assessed the effectiveness of cetuximab combined with chemotherapy in this setting. Methods: Between Dec 2, 2004, and March 27, 2008, 114 patients were enrolled from 17 centres in Germany and Austria; three patients receiving FOLFOX6 alone were excluded from the analysis. Patients with non-resectable liver metastases (technically non-resectable or ≥5 metastases) were...
